Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome
Issued Date
2022-08-01
Resource Type
eISSN
20770383
Scopus ID
2-s2.0-85136194285
Journal Title
Journal of Clinical Medicine
Volume
11
Issue
15
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine Vol.11 No.15 (2022)
Suggested Citation
Jitrukthai S., Kositamongkol C., Boonchai P., Mepramoon E., Ariyakunaphan P., Nimitpunya P., Srivanichakorn W., Chaisathaphol T., Washirasaksiri C., Auesomwang C., Sitasuwan T., Tinmanee R., Sayabovorn N., Charatcharoenwitthaya P., Phisalprapa P. Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome. Journal of Clinical Medicine Vol.11 No.15 (2022). doi:10.3390/jcm11154627 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87266
Title
Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome
Author's Affiliation
Other Contributor(s)
Abstract
Metabolic syndrome (MetS) patients are at higher risk for nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular diseases (ASCVD), and death. Given a lack of longitudinal data on patients with MetS in Southeast Asia, this study investigated the incidence of NAFLD and ASCVD and the all-cause mortality rate during a 10-year follow-up of Thai patients with MetS. Retrospective data were collected on 496 MetS patients with ultrasonography or transient elastography results. The patients had been followed up continuously by a university hospital between October 2011 and November 2021, and their mean age was 61.0 ± 10.9 years. Patients with secondary causes of hepatic steatosis were excluded. Cox proportional hazards regression models with time-varying covariates were adopted. During the 10-year follow-up, 17 patients (11.2%) developed NAFLD, and 27 (6.4%) developed ASCVD. The NAFLD and ASCVD incidence rates were 21.7 and 10.9 events per 1000 person years, respectively. The mortality rate was 14.2 deaths per 1000 person years. The prevalence of hypertension, dyslipidemia, ASCVD, NAFLD, advanced fibrosis, and cirrhosis at baseline was significantly higher in the nonsurvival group. The NAFLD incidence and mortality rate of patients with MetS were lower than those in previous studies. Intensive, holistic, and continuous care should be considered for better outcomes.